Valtier S, Cody J T
Wilford Hall Medical Center/RD, Lackland AFB, TX 78236-5319, USA.
J Anal Toxicol. 1995 Oct;19(6):375-80. doi: 10.1093/jat/19.6.375.
Deuterium-labeled analogues are available for a variety of drugs, but the amphetamines (amphetamine and methamphetamine) have more options available than any other drug. The analytical method and circumstances of its use can have a significant impact on the decision of what is the best internal standard to use. More than one method can give acceptable results; however, some circumstances can make a given internal standard a poor choice for a particular analysis. Increased choices of available candidates make the evaluation of an internal standard even more difficult. Thorough evaluation of the available options is a major undertaking and is presented here to assist laboratories in selection of the most appropriate internal standard for their individual needs. All commercially available deuterated analogues to amphetamine and methamphetamine were evaluated as part of this study. in addition, nonisotopically labeled propylamphetamine was also evaluated for comparison purposes. The compounds were analyzed underivatized and derivatized with trifluoroacetic anhydride, pentafluoropropionic anhydride, heptafluorobutyric anhydride, and 4-carbethoxyhexafluorobutyryl chloride on HP-1, HP-5, and DB-I 7 capillary columns. Mass spectral analysis revealed that several of the internal standards were not viable for monitoring ions typically associated with selected ion monitoring analysis of amphetamine and methamphetamine. These included amphetamine-d3 (1-phenyl-2-aminopropane-3,3,3-d3) and amphetamine-d5 (phenyl-d5), neither of which exhibits three unique ions. The d3 standard shares the common ion at m/z 91, acid d5 (phenyl) shares the base peak ion with derivatized amphetamine. Although methamphetamine-d6 and methamphetamine-d10 show three unique ions, they do not allow monitoring of the ion fragments typically used for methamphetamine. Evaluation of the limit of detection, linear range, and within-run and between-run variability was accomplished for each viable internal standard.
氘标记类似物可用于多种药物,但苯丙胺类药物(苯丙胺和甲基苯丙胺)比其他任何药物都有更多可用选项。其分析方法和使用情况会对选择何种最佳内标产生重大影响。不止一种方法可得出可接受的结果;然而,某些情况可能会使特定内标在特定分析中成为糟糕的选择。可用候选物的选择增加使得对内标的评估更加困难。对可用选项进行全面评估是一项重大任务,此处予以呈现以帮助实验室根据其各自需求选择最合适的内标。作为本研究的一部分,对所有市售的苯丙胺和甲基苯丙胺的氘代类似物进行了评估。此外,还评估了非同位素标记的丙基苯丙胺用于比较目的。这些化合物在未衍生化的情况下以及用三氟乙酸酐、五氟丙酸酐、七氟丁酸酐和4 - 乙氧羰基六氟丁酰氯进行衍生化后,在HP - 1、HP - 5和DB - I 7毛细管柱上进行分析。质谱分析表明,有几种内标不适用于监测通常与苯丙胺和甲基苯丙胺的选择离子监测分析相关的离子。其中包括苯丙胺 - d3(1 - 苯基 - 2 - 氨基丙烷 - 3,3,3 - d3)和苯丙胺 - d5(苯基 - d5),它们都没有显示出三个独特的离子。d3内标在m/z 91处有共同离子,d5(苯基)内标与衍生化的苯丙胺共享基峰离子。尽管甲基苯丙胺 - d6和甲基苯丙胺 - d10显示出三个独特的离子,但它们不允许监测通常用于甲基苯丙胺的离子碎片。对每个可行的内标完成了检测限、线性范围以及批内和批间变异性的评估。